The story of Sildenafil presents a complex picture for shareholders. While the initial launch generated substantial gains, the lapse of its exclusive rights opened the door to cheaper versions, dramatically reducing https://bookmarkinglog.com/story21670833/the-copyright-and-the-pharmaceutical-industry-a-precarious-bet